Biogen Inc.

Biogen Inc. is a biopharmaceutical company that discovers, develops, manufactures, and delivers treatments for neurological and neurodegenerative diseases. The company has a portfolio of innovative therapies that include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA treating multiple sclerosis, SPINRAZA for spinal muscular atrophy, FUMADERM for treating plaque psoriasis, and BENEPALI, an etanercept biosimilar referencing ENBREL, among others. It also manufactures ADUHELM for the treatment of Alzheimer’s disease, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE.

Biogen’s products also include RITUXAN, used for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and other conditions, and GAZYVA to treat CLL and follicular lymphoma. The company also recently developed OCREVUS, an important treatment for relapsing MS and primary progressive MS. On top of that, they are continually developing new therapies such as BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 for Alzheimer’s and dementia; BIIB067, BIIB078, BIIB105, BIIB100 and BIIB110 for neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for Parkinson’s and movement disorders; BIIB125 and BIIB104 for neuropsychiatry, Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 for acute neurology; and BIIB074 for neuropathic pain. They are also developing BYOOVIZ, BIIB800, and SB15 biosimilars.

Since its founding in 1978, Biogen has continued to remain at the forefront of scientific innovation and technological advancement by collaborating with numerous partners. These partnerships have enabled them to expand the potential of their treatments and to provide better health outcomes for those living with neurological and neurodegenerative diseases. Through partnerships with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., Biogen has achieved significant progress in treating neurological and neurodegenerative diseases.

Biogen also has plans to continue their research and development into new treatments. Recently, the company announced plans to invest $100 million to build a new biomanufacturing facility in Research Triangle Park, North Carolina. This new facility will support the company’s long-term growth plans by providing additional resources to allow them to develop more drugs and treatments for neurological and neurodegenerative diseases. Moreover, Biogen has collaborated with the US-based biotechnology company, C4 Therapeutics, to develop and commercialize treatments for neurodegenerative diseases. This collaboration leverages C4 Therapeutics’ platform for targeting disease-causing protein-protein interactions with novel, small-molecule therapeutics and Biogen’s expertise in neurology.